Details of the Drug

General Information of Drug (ID: DM90GS3)

Drug Name

VK-0214

Synonyms

6FGG71NJ3Y; VK0214; VK-0214; UNII-6FGG71NJ3Y; (((4-(3-Benzyl-4-hydroxybenzyl)-3,5-dimethylphenyl)oxy)methyl)phosphonic acid; ((4-(3-Benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid; Phosphonic acid, P-((4-((4-hydroxy-3-(phenylmethyl)phenyl)methyl)-3,5-dimethylphenoxy)methyl)-; 852949-30-5; SCHEMBL283442; CHEMBL4802139

Indication

Disease Entry	ICD 11	Status	REF
X-linked Adrenoleukodystrophy	5C57	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C23H25O5P
Canonical SMILES: CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)CC3=CC=CC=C3)C)OCP(=O)(O)O
InChI: InChI=1S/C23H25O5P/c1-16-10-21(28-15-29(25,26)27)11-17(2)22(16)14-19-8-9-23(24)20(13-19)12-18-6-4-3-5-7-18/h3-11,13,24H,12,14-15H2,1-2H3,(H2,25,26,27)
InChIKey: GFJCILQBXUTOGN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 15942270
TTD ID: DJ74CB

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thyroid hormone receptor beta (THRB)	TTGER3L	THB_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04973657) Phase 1b, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, PD and PK of VK0214, in Subjects With the Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Viking Therapeutics